临床与病理杂志2025，Vol.45Issue(8)：941-950,10.DOI:10.11817/j.issn.2095-6959.2025.250099
基于生物信息学分析MAPRE1在卵巢癌中的表达及其临床意义
Bioinformatics-based analysis of MAPRE1 expression and its clinical significance in ovarian cancer
摘要
Abstract
Objective:Ovarian cancer is the fifth leading cause of cancer-related death among women worldwide,posing a serious threat to women's health and life.Identifying effective biomarkers and therapeutic targets is of great importance for the diagnosis and treatment of ovarian cancer.This study aims to investigate the expression of microtubule-associated protein progesterone receptor/end binding family member 1(MAPRE1)in ovarian cancer and its clinical significance. Methods:Sequencing data and relevant clinical information of the MAPRE1 gene were obtained from the Cancer Genome Atlas(TCGA)and the Genotype-Tissue Expression(GTEx)databases.Real-time quantitative PCR was used to detect MAPRE1 mRNA in 12 pairs of ovarian cancer and adjacent normal tissues and to analyze correlations with methyltransferase-and mismatch repair-related gene expression.Protein expression of MAPRE1 in ovarian cancer and adjacent normal tissues was analyzed using the University of Alabama at Birmingham Cancer Data Analysis Portal(UALCAN)and the Human Protein Atlas(HPA)database.The prognostic value of MAPRE1 was evaluated using the Kaplan-Meier Plotter database.The correlation between MAPRE1 expression and immune cell infiltration was analyzed using the Tumor Immune Estimation Resource(TIMER)database.Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway analyses were performed using Gene Set Enrichment Analysis(GSEA)on MAPRE1 co-expressed genes in ovarian cancer. Results:Both mRNA and protein levels of MAPRE1 were significantly higher in the ovarian cancer tissues than those in the adjacent normal tissues(both P<0.01).MAPRE1 expression was significantly associated with patient age and tumor residue(P=0.009 and P=0.011,respectively).Kaplan-Meier analysis indicated that high MAPRE1 expression was correlated with poorer prognosis in ovarian cancer patients(P<0.001).In patients receiving single-agent paclitaxel,single-agent platinum,or combined paclitaxel alone,and platinum therapy,high MAPRE1 expression was also associated with worse prognosis(P=0.003,P=0.002,and P=0.004,respectively).MAPRE1 expression showed positive correlations with DNA(cytosine-5)-methyltransferase(DNMT)1,tRNA aspartic acid methyltransferase 1(TRDMT1),DNMT3A,and DNMT3B(all P<0.05),as well as with mismatch repair genes MutL homolog 1(MLH1),MutS homolog(MSH)2,MSH6,and postmeiotic segregation increased 2(PMS2)(all P<0.05).TIMER analysis showed that MAPRE1 expression was positively correlated with T helper(Th)cells,Th2 cells,natural killer(NK)cells,follicular helper T(TFH)cells,and effector memory T(Tem)cells,but negatively correlated with cytotoxic cells,activated dendritic cell(aDCs),Th17 cells,NK CD56bright cells,and plasmacytoid dendritic cells(pDCs).GO analysis suggested that MAPRE1 co-expressed genes were mainly involved in β-catenin-related and ribonucleotide-binding activities.KEGG analysis demonstrated that MAPRE1 participated in the cell cycle and mammalian target of rapamycin(mTOR)signaling pathways. Conclusion:MAPRE1 is highly expressed in ovarian cancer and is associated with prognosis,immune cell infiltration,DNA methylation,and mismatch repair proteins.It may promote the occurrence and progression of ovarian cancer through the cell cycle and mTOR signaling pathways.关键词
微管相关蛋白RP/EB家族成员1/卵巢癌/生物信息分析/预后/免疫细胞浸润Key words
microtubule-associated protein progesterone receptor/end binding family member 1/ovarian cancer/bioinformatics analysis/prognosis/immune cell infiltration引用本文复制引用
孟令超,卢成陆,杨彩英,刘春玲..基于生物信息学分析MAPRE1在卵巢癌中的表达及其临床意义[J].临床与病理杂志,2025,45(8):941-950,10.基金项目
河北省医学科学研究课题计划(20191617).This work was supported by the Medical Science Research Project of Hebei Province,China(20191617). （20191617）
